KRAS and cancer: For example, the predicted sensitivity to mTOR inhibitors in the high-risk group contrasts with some preclinical evidence suggesting that KRAS-driven cancers, potentially relevant to pathways enriched in our high-risk group, might exhibit resistance to PI3K/mTOR pathway inhibition (70).